- Raised $8M Series B, Jul 2018
- Raised $2.3M grant, Sep 2020
- Raised $650k Series A, Feb 2016
About
MyBiotics Pharma is a clinical-stage microbiome company that discovers and develops live bacteria-based products aimed at restoring microbial equilibrium for the biopharmaceutical and supplement markets. The company utilizes proprietary technologies for culturing, formulation, and production to enable improved viability, efficient delivery, and colonization of beneficial live bacteria. Their technology platform includes MyCrobe (single strain fermentation and formulation technology), SuperDonor (microbiome production and recovery technology), SuperDonor Select (next-generation multi-strain technology), and MyLiveIn (AI-enabled design platform). MyBiotics focuses on developing treatments for conditions such as Clostridium difficile infection (CDI), women's health (bacterial vaginosis), immuno-oncology, and NASH.
Funding history · 5 rounds · $10.9M total
Headcount over time
Q&A
- What is MyBiotics Pharma's primary focus?
- MyBiotics Pharma is a clinical-stage microbiome company that develops live bacteria-based products to restore microbial equilibrium for biopharmaceutical and supplement markets.
- What is the total amount of funding MyBiotics Pharma has raised to date?
- MyBiotics Pharma has raised a total of $13,479,356 in funding.
- When did MyBiotics Pharma complete its Phase I trial for MBX-SD-202?
- MyBiotics Pharma announced the successful completion of the Phase I trial for its MBX-SD-202 whole microbiome treatment in January 2022.
- Which fund invested in MyBiotics Pharma's A Round in February 2021?
- In February 2021, MyBiotics Pharma received an investment in its A Round from Mii Fund.
- What is the employee count for MyBiotics Pharma?
- MyBiotics Pharma currently has 12 employees, falling within the 11-50 employee bucket.
- What are some of the key technologies developed by MyBiotics Pharma?
- MyBiotics Pharma utilizes proprietary technologies including MyCrobe, SuperDonor, SuperDonor Select, and MyLiveIn, an AI-enabled design platform.
- What areas of health is MyBiotics Pharma focusing on for treatment development?
- MyBiotics Pharma is focused on developing treatments for conditions such as Clostridium difficile infection (CDI), women's health (bacterial vaginosis), immuno-oncology, and NASH.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | mybiotics-pharma.com/ |
|---|---|
| linkedin.com/company/6381842 | |
| YouTube | youtube.com/channel/UCHyT6ZnVW9WRjfpx2On7-Tw |
Identifiers & details
| Legal name | MYBIOTICS PHARMA LTD |
|---|---|
| Former names | MyBiotix Pharma |
| Founded | 2014-7 |
| Employees (exact) | 12 |
Radar intelligence
Patents
| EPO | 9 |
|---|
Web history (Wayback)
| Domain | mybiotics-pharma.com |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515094514 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2014-06-12 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 1 — charge (1) |
| Registered address | שד אבא אבן 12 הרצליה |
Recent registry events
| Date | Event |
|---|---|
| 2026-04-23 | סילוק שעבוד |